Mounjaro and Hyperthyroidism: What the Evidence Says

What the prescribing guidance and trial data tell us about thyroid conditions and Mounjaro

The Mounjaro SmPC, published on the electronic Medicines Compendium, does not list hyperthyroidism as a direct contraindication to tirzepatide. What it does flag (clearly and specifically) is a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), because animal studies raised a theoretical signal for thyroid C-cell tumours with GLP-1 receptor agonists. It is important to understand that MTC and MEN2 are distinct conditions from hyperthyroidism, which is caused by an overactive thyroid gland, most often due to Graves' disease, a toxic multinodular goitre, or thyroiditis. These are not the same diagnoses, and conflating them causes unnecessary anxiety. That said, any thyroid history (including hyperthyroidism, current thyroid medication, or a history of thyroid surgery or radioiodine treatment) should be declared in full when you complete your consultation. The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled thousands of adults with obesity across a wide range of comorbidities, and the detailed results were reviewed by NICE when it appraised tirzepatide. However, participants with poorly controlled endocrine conditions were typically excluded from phase-three trials, which means we have limited direct trial evidence for people with active, untreated hyperthyroidism specifically. That uncertainty matters, and it is precisely why the prescriber's individual review exists.

How an overactive thyroid can complicate the picture for tirzepatide

Hyperthyroidism raises your basal metabolic rate, often causes unintended weight loss in its own right, and can produce a rapid or irregular heartbeat. Tirzepatide, as a dual GIP and GLP-1 receptor agonist, suppresses appetite and slows the rate at which your stomach empties. Where the two conditions interact clinically, the concern is less about a direct drug-thyroid interaction and more about layered physiological effects that need monitoring. If you are already losing weight because of an overactive thyroid, adding a medicine that further reduces appetite and caloric intake could accelerate that loss to an unhealthy degree. Rapid, uncontrolled weight loss carries its own risks, including lean muscle loss, nutritional deficiency, and in some cases bone density changes. The NHS patient information page for tirzepatide outlines the side-effect profile, which is largely gastrointestinal: nausea, loose stools, and reduced appetite are common, especially in the early weeks of treatment. For someone whose thyroid is already driving weight loss and GI symptoms, those effects could be harder to tolerate or to interpret. Your prescriber and your thyroid specialist need to be aware of each other's plans. That is not a bureaucratic ask; it is genuinely safer care.

What 'controlled' versus 'uncontrolled' hyperthyroidism means for your eligibility

If your hyperthyroidism is well controlled (you are stable on carbimazole, propylthiouracil or block-and-replace therapy, your thyroid function tests are within the target range, and your endocrinologist is satisfied with your current status) the prescribing picture is more straightforward. A prescriber can review your full history, weigh the risks and benefits for you as an individual, and make an informed decision. If, on the other hand, your thyroid condition is newly diagnosed, recently changed in severity, or actively being investigated, most prescribers will reasonably want to see it stabilised first. Starting a new prescription medicine while your underlying condition is still in flux makes it harder to attribute any new symptoms correctly and adds unnecessary complexity to your care. The NICE appraisal of tirzepatide (TA1026) sets out the licensed eligibility criteria for Mounjaro: a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. Hyperthyroidism itself is not one of the listed weight-related qualifying conditions, but obesity is a health issue in its own right and many people with well-controlled hyperthyroidism still carry excess weight. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. Suitability, however, is always a clinical judgement, not a tick-box exercise. Our prescribers look at the whole picture, including your thyroid history, current treatment and any recent blood results you can share.

Who to speak to, and what to bring to your consultation

The most useful thing you can do before starting any conversation about tirzepatide is to speak with your GP or endocrinologist about your current thyroid status. Ask whether your thyroid function tests are at target and whether your specialist sees any reason a weight-loss medicine might complicate your care. Then bring that context to your consultation with us. If you take any thyroid medication, include the name, dose and how long you have been on it. If you have had radioiodine treatment or thyroid surgery, include when and why. The more complete the picture, the more confidently a prescriber can act. You can find out how tirzepatide may affect thyroid function more broadly, and if you want a detailed look at how Mounjaro interacts with the thyroid, that page brings together the clinical evidence in one place. If your situation involves an underactive thyroid rather than an overactive one, you can read about whether Mounjaro is suitable if you have hypothyroidism, which covers the relevant considerations for that condition. For anyone thinking about treatment and conception at the same time, Mounjaro is not recommended during pregnancy or while breastfeeding, and there is dedicated guidance on taking Mounjaro while trying to conceive that is worth reading before you book a consultation. Our clinical team, whose background and qualifications you can read about on the clinical team page, reviews every submission the same working day. Order your consultation before 12pm and, if you are found clinically suitable, treatment is dispatched that day. If you are ready to take that step, start your free consultation and let a prescriber look at your full picture.